RxDoctor Payments DataLook up a doctor →

Diane Ross, MD

Neurology · Gulfport, MSNPI 1447323001

Payments from drug & device makers

$9,607in general payments, 2019–2025

Across 579 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • Acadia Pharmaceuticals Inc$976
  • SK Life Science, Inc.$744
  • AbbVie$701
  • Teva Pharmaceuticals USA, Inc.$539
  • Pfizer$481
  • plus $5K from 40 others

What the payments were for

  • Speaking & faculty fees$551%
  • Food & beverage$9,42498%
  • Education$1281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,607 in reported general payments places this provider in the 65th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$125,661
Medicare patients
479
Services billed
1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate37$205,091
Kesimpta PenOfatumumab21$175,744
IngrezzaValbenazine Tosylate13$166,284
BriviactBrivaracetam72$110,227
Nurtec OdtRimegepant Sulfate66$92,326
QuliptaAtogepant69$80,424
Emgality PenGalcanezumab-Gnlm80$73,834
UbrelvyUbrogepant40$70,234
Aimovig AutoinjectorErenumab-Aooe63$61,158
RytaryCarbidopa/Levodopa35$53,895
FycompaPerampanel30$48,410
XcopriCenobamate21$45,510
Lacosamide135$25,054
RexultiBrexpiprazole14$21,201
Keppra XrLevetiracetam12$12,665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$976$205,09137 claims
Neurocrine Biosciences, Inc.Ingrezza$115$166,28413 claims
AbbVieQulipta, Ubrelvy$701$150,658109 claims
UCB, Inc.Briviact, Nayzilam$1,367$118,45385 claims
PfizerNurtec Odt$481$92,32666 claims
Amneal Pharmaceuticals LLCRytary$181$53,89535 claims
Eisai Inc.Fycompa$467$48,41030 claims
SK Life Science, Inc.Xcopri$744$45,51021 claims
Otsuka America Pharmaceutical, Inc.Rexulti$137$21,20114 claims
Upsher-smith Laboratories LLCTopiramate$27$2,639200 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 neurology providers in Mississippi.

Other neurology in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →